Trial Profile
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Vosilasarm (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors Radius Health Inc.
- 15 Oct 2020 Status changed from active, no longer recruiting to completed.
- 14 Dec 2019 Results determining maximum tolerated dose and recommended dose for RAD140 were presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 06 Dec 2019 According to a Radius Health media release, data from this study will be presented at the upcoming 2019 San Antonio Breast Cancer Symposium, on December 13 in San Antonio, Texas